Karthik Kuppusamy
Known title: SVP, Clinical SolutionsCIK: 0001955217
Associated companies
Transaction History
| DGX | ▼ Sell | Other | 37 | $8K | 7/22/2026 | View on chart |
| DGX | ▲ Buy | Option Exercise | 3,320 | $424K | 6/4/2026 | View on chart |
| DGX | ▲ Buy | Option Exercise | 4,827 | $588K | 6/4/2026 | View on chart |
| DGX | ▼ Sell | Open Market | 8,147 | $1.6M | 6/4/2026 | View on chart |
| DGX | ▼ Sell | Other | 39 | $8K | 4/20/2026 | View on chart |
| DGX | ▲ Buy | Grant | 6,200 | $1.3M | 3/4/2026 | View on chart |
| DGX | ▼ Sell | Open Market | 2,628 | $538K | 3/4/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 205 | $42K | 3/2/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 259 | $54K | 2/18/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 252 | $53K | 2/18/2026 | View on chart |
| DGX | ▲ Buy | Grant | 2,135 | $0 | 2/18/2026 | View on chart |
| DGX | ▼ Sell | Other | 16 | $3K | 1/28/2026 | View on chart |
| DGX | ▲ Buy | Grant | 15 | $3K | 10/21/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 123 | $22K | 8/13/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 2,210 | $376K | 7/31/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 3,045 | $510K | 7/30/2025 | View on chart |
| DGX | ▲ Buy | Option Exercise | 5,224 | $586K | 7/30/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 5,224 | $874K | 7/30/2025 | View on chart |
| DGX | ▲ Buy | Option Exercise | 3,045 | $264K | 7/30/2025 | View on chart |
| DGX | ▼ Sell | Other | 27 | $5K | 7/21/2025 | View on chart |
| DGX | ▼ Sell | Other | 27 | $4K | 4/21/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 2,555 | $434K | 4/2/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 1,879 | $326K | 3/4/2025 | View on chart |
| DGX | ▲ Buy | Grant | 4,434 | $770K | 3/4/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 992 | $172K | 3/3/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 233 | $40K | 2/26/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 287 | $49K | 2/19/2025 | View on chart |
| DGX | ▲ Buy | Grant | 2,269 | $0 | 2/12/2025 | View on chart |
| DGX | ▼ Sell | Other | 12 | $2K | 1/29/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 1,775 | $279K | 10/28/2024 | View on chart |
| DGX | ▼ Sell | Other | 21 | $3K | 10/21/2024 | View on chart |
| DGX | ▼ Sell | Open Market | 1,990 | $305K | 8/28/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 74 | $11K | 8/14/2024 | View on chart |
| DGX | ▼ Sell | Other | 31 | $5K | 7/22/2024 | View on chart |
| DGX | ▼ Sell | Open Market | 1,760 | $246K | 4/29/2024 | View on chart |
| DGX | ▲ Buy | Grant | 45 | $6K | 4/22/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 205 | $26K | 2/28/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 68 | $9K | 2/28/2024 | View on chart |
| DGX | ▲ Buy | Grant | 2,039 | $255K | 2/23/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 619 | $77K | 2/23/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 102 | $13K | 2/21/2024 | View on chart |
| DGX | ▲ Buy | Grant | 2,641 | $0 | 2/14/2024 | View on chart |
| DGX | ▲ Buy | Grant | 29 | $4K | 1/31/2024 | View on chart |
| DGX | ▲ Buy | Grant | 30 | $4K | 10/23/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 74 | $10K | 8/15/2023 | View on chart |
| DGX | ▲ Buy | Grant | 25 | $4K | 7/25/2023 | View on chart |
| DGX | ▼ Sell | Other | 25 | $4K | 4/24/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 583 | $86K | 3/6/2023 | View on chart |
| DGX | ▲ Buy | Grant | 1,985 | $294K | 3/6/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 65 | $9K | 3/1/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 195 | $29K | 2/23/2023 | View on chart |
| DGX | ▲ Buy | Grant | 2,094 | $0 | 2/23/2023 | View on chart |
| DGX | ▼ Sell | Other | 13 | $2K | 2/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.